Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalotuzumab in Metastatic Neuroendocrine Tumors
NCT00610129Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2008
- Primary completion
- Jan 2010
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dalotuzumab in Neuroendocrine Neoplasm (NEN), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Objective Response Rate at 2 years. Started Jan 2008; status: completed.
02
Drugs
dalotuzumab
03
Conditions
Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00610129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00610129.